Synthesis and biological evaluation of 20-epi-amino-20-deoxysalinomycin derivatives
25
Citation
27
Reference
10
Related Paper
Citation Trend
Keywords:
Salinomycin
Druggability
Mode of Action
Salinomycin is a monocarboxylic acid polyether antibiotics produced by Streptomyces albus. It has strong inhibiting and killing activity against most gram-positive bacteria and various coccidiums with low adverse impact on environment. In addition, salinomycin can specifically inhibit the growth of a variety of cancer cells and cancer stem cells via targeting to multiple sites, and is a promising anti-tumor drug candidate. To obtain high yield salinomycinproducing strain, conventional mutation techniques and modern molecular genetic methods have been used. Meanwhile, bioactivity and selectivity of salinomycin could be improved by modifying the chemical structure and changing drug delivery methods. Here, we summarize the key strategies for enhancing salinomycin production and review the progresses in optimizing its drug activity and targeting properties. The future research focus is also addressed.
Salinomycin
Streptomyces albus
Cite
Citations (1)
We have employed semisynthesis to enhance the anticoccidial potency of a polyether ionophore. CP-72,588 is the alpha-methyl analog of the fermentation-derived polyether ionophore UK-58,852. The parent ionophore required a dose of 15 ppm to achieve anticoccidial efficacy in chickens equivalent to that of salinomycin at 60 ppm. CP-72,588 demonstrated substantially improved potency, with efficacy at 5 to 7.5 ppm. The intrinsic antimicrobial potencies of the two ionophores are similar; however, CP-72,588 was found in chicken tissues at higher levels than those of the parent ionophore when each was administered at the same dose (8 ppm). The enhanced potency of CP-72,588 may be partially due to enhanced uptake into tissues.
Salinomycin
Semisynthesis
Cite
Citations (0)
Salinomycin
Streptomycetaceae
Streptomyces albus
Strain (injury)
Cite
Citations (263)
Salinomycin (Coxistac)1, a new broad spectrum anticoccidial, was tested in broilers reared in floor pens for safety at 50, 60, 80, 100, and 160 ppm fed continuously from 1 to 56 days of age. Four trials were conducted. Comparisons were made to unmedicated controls and in three trials to monensin at 80, 100, and 121 ppm. The weight gains at 50 and 60 ppm of salinomycin and 80 and 100 ppm of monensin were statistically comparable and equivalent to or better than controls. The weight gain at 80 ppm of salinomycin was slightly below controls but comparable to 121 ppm monensin. Levels of 100 and 160 ppm of salinomycin depressed weight gain. Feed conversion for all treatments except 160 ppm salinomycin were comparable.
Salinomycin
Cite
Citations (16)
Salinomycin
Lasalocid
Cite
Citations (2)
Five 7-day trials using 336, 24, 24, 40, and 40 Large White male turkeys when 7, 11, 15, 27, and 32 weeks of age, respectively, were conducted to determine the toxic effects of salinomycin. Salinomycin became more toxic as the age of the turkeys increased. When 7-week-old turkeys were fed diets containing 44 or 66 ppm salinomycin, only 1 of 84 died; when turkeys 27 or 32 weeks of age were fed those amounts, 13 of 20 died. Salinomycin at 22 ppm tended to depress rate of growth at young ages and to prevent or decrease growth and to increase mortality at older ages. Caution should be exercised to avoid salinomycin contamination of turkey diets.
Salinomycin
Cite
Citations (48)
Prophylactic levels of three ionophorous antibiotics, monensin, salinomycin, and lasalocid, were administered to groups of chickens and turkeys. All three ionophores markedly inhibited invasion of cecal tissues by sporozoites of ionophore-sensitive (IS) Eimeria tenella. Monensin and salinomycin also reduced invasion in turkeys by sporozoites of E. adenoeides, but lasalocid only minimally inhibited invasion. Invasion of ceca of monensin-medicated chickens was significantly greater by sporozoites of ionophore-resistant (IR) E. tenella than of the IS isolate. Concomitant experiments showed significant differences in [14 C]monensin accumulation among IS and IR isolates of E. tenella. The decreased uptake of monensin by the IR isolates appeared to be accompanied by a decrease in responsiveness to the activity of monensin as well as to two other ionophores, salinomycin and narasin in cell culture. The amount of monensin, salinomycin or narasin required to inhibit development of E. tenella by 50% was 20 to 40 times higher for the IR isolates than for the IS ones. Collectively, the data suggest that differences in ionophore accumulation by IS and IR isolates of E. tenella might reflect differences in membrane chemistry and that these differences are responsible for the expressions of resistance that were observed in these studies. This expression of resistance appears to be common to all ionophores tested.
Salinomycin
Monensin
Lasalocid
Cite
Citations (46)
Salinomycin
Monensin
Lasalocid
Mode of Action
Eimeria acervulina
Cite
Citations (3)
Salinomycin is a chemotherapeutic drug commonly used to inhibit the growth of tumor and specifically kill the cancer stem cells (CSC).The anti-cancer effect of salinomycin has attracted extensive attention at home and abroad,whihc is realized by inducing cancer cell apoptosis,suppressing cancer cell proliferation and invasion and reducing drug resistance.
Key words:
Neoplasms ; Neoplastic stem cells ; Salinomycin
Salinomycin
Cite
Citations (0)
A study was conducted to evaluate the effects of feeding salinomycin at the recommended prophylactic level, and at 2 and 3 times this level, to finishing male broilers (d 21 to 38). Four treatment groups were given the experimental diets containing 0, 60, 120, or 180 parts per million (ppm) salinomycin from d 21 to 38. Performance, relative organ weights, selected serum enzymes, and salinomycin residues in liver, muscle, and serum were determined. Salinomycin supplementation had no effect on body weight, feed intake, or feed conversion, and caused no overt signs of toxicity. After a week of being fed the salinomycin diets, the serum activity of aspartate aminotransferase was significantly increased in chickens fed 180 ppm compared with controls. These birds also showed microscopic lesions in breast and thigh muscles, but not in cardiac muscle. Salinomycin residues were not detected by high-performance liquid chromatography coupled to tandem mass spectrometry in liver or muscle samples from the birds fed 0, 60, or 120 ppm salinomycin. However, chickens fed 180 ppm salinomycin had detectable levels in liver and muscle above the maximum residue level of 5 μg/kg established by the European Union. All birds fed salinomycin had salinomycin in their sera with levels ranging from N.D. (not detected) in the controls to 24.4 ± 7.9, 61.4 ± 18.9, and 94.5 ± 9.1 μg/L for salinomycin dietary levels of 60, 120, and 180 ppm, respectively. Serum salinomycin concentration was linearly related with salinomycin content in feed (y = 0.584x - 10, r2 = 0.999). The results showed that even at 3 times the prophylactic level, salinomycin does not induce clinical toxicosis or mortality. No salinomycin residues were found in edible tissues at the recommended dietary level or at 2 times this level. However, salinomycin was detected in serum regardless of the dietary level. A simple method for salinomycin determination in serum is described which can be used as a marker of exposure and/or to predict levels in the diet.
Salinomycin
Monensin
Cite
Citations (4)